Premium
Serum calcitonin gene‐related peptide levels in untreated prostate cancer patients
Author(s) -
SUZUKI KAZUMI,
KOBAYASHI YUTAKA,
MORITA TATSUO
Publication year - 2006
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01402.x
Subject(s) - medicine , prostate cancer , calcitonin gene related peptide , calcitonin , immunoradiometric assay , prostate , radioimmunoassay , prostate specific antigen , pca3 , endocrinology , cancer , oncology , urology , gastroenterology , neuropeptide , receptor
Background: The role of calcitonin gene‐related peptide (CGRP) in prostate cancer has not been fully understood. Moreover, the serum CGRP level in prostate cancer patients has never been reported. We measured the serum CGRP levels in untreated prostate cancer patients to elucidate its clinical significance. Materials and methods: We used 36 serum samples from prostate cancer patients. All patients had never received any treatment. Serum CGRP was measured by immunoradiometric assay, and we analysed the association between serum CGRP level and clinicopathological factors. Results: Serum CGRP levels in the patients with higher clinical stages and histological grade were significantly higher than in those with lower stages and grade, respectively. But the levels did not correlate with the patient’s age, liver or renal functions, serum prostate‐specific antigen levels. Conclusion: Serum CGRP levels were significantly elevated in the patients with high grade or high stage untreated prostate cancer patients. Measurement of the serum CGRP may be a useful predictor of staging or grading of prostate cancer in the untreated prostate cancer patients.